HANNOVER, March 3 /PRNewswire/ -- BioVisioN AG announces that a licensing contract has been closed with F. Hoffmann-La Roche Ltd. (Roche) regarding BioVisioN's patent on the Differential Peptide Display (DPD) technology that allows one to comprehensively visualise the peptides and small proteins (peptidome) within a sample and to analyse changes within the peptidome. Using this technology it is possible to discover a.o. diagnostic biomarkers in human tissue and body fluids. The license allows Roche to use the patent non-exclusively for in-house purposes.
Dr. Sven Rohmann, CEO of BioVisioN, stated, "It is a confirmation of the value of our efforts that such a renowned company as Roche wants to use our technology for its research."
BioVisioN AG is an independent biotech company in Hannover, Germany. Founded in 1997 by Dr. Peter Schulz-Knappe, Dr. Michael Schrader, Prof. Dr. Dr. Wolf-Georg Forssmann and Dr. Hans-Georg Opitz, it now has 45 employees. The most important partners hitherto are Roche Diagnostics GmbH (Germany), Novo Nordisk A/S (Denmark), AstraZeneca Ltd. (UK), Applied Biosystems (USA), Matrix Science Ltd. (UK) and the Swiss Institute for Research in Allergy and Asthma.
BioVisioN AG specializes in the identification of disease-relevant peptides and proteins using its proprietary Peptidomics(TM) technologies in order to discover new diagnostic markers, or biomarkers and therapeutic leads and targets. Apart from research collaborations, BioVisioN provides access to its technology also in fee-for-service contracts as a Biological Research Organisation.
Further information can be found on our new website http://www.biovision-discovery.de/
CONTACT: Dr. Rainer Voegeli, Head of Business Development for BioVisioNAG, +49-0-511-538-896-0, Fax - +49-0-511-538-896-66,email@example.com